Teva’s Pay – For Delay Settlement Restricts Brand-Generic Deals

Teva’s Pay-For-Delay Settlement Restricts Brand-Generic Deals / $1.2 billion agreement resolving Provigil litigation with FTC blocks Teva from entering business deal with competitor until 30 days after patent settlement that restricts generic entry, sets $7 million cap on litigation savings. /read more

Faster FDA Review A Possibility For Celldex’s Rintega After Phase II / Celldex presented positive data from a Phase II study testing the therapeutic cancer vaccine Rintega in patients with EGFRvIII-positive recurrent read more

Merck Expands Keytruda Trial Collaboration With Amgen, Unveils Others / Merck’s sBLA for Keytruda in lung cancer has been accepted by FDA and granted an Oct. 2 action date, the firm announced. The company also revealed several new research collaborations to study Keytruda in more combination trials at ASCO. / read more

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.